EP4433471A1: N-(2H-Indazol-5-yl)pyrazine-2-carboxamide Derivatives as HTT Modulators for Huntington's Disease
Summary
The EPO published patent application EP4433471A1 disclosing N-(2H-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as HTT (huntingtin protein) modulators for the treatment of Huntington's disease. The applicant is CHDI Foundation, Inc., a nonprofit research organization focused on Huntington's disease therapeutics. The application covers novel chemical entities designed to modulate HTT function, with designated states spanning 32 European countries including DE, FR, GB, IT, NL, ES, PL, SE, and others under the EPC.
“N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE”
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.
What changed
The EPO published patent application EP4433471A1 disclosing novel pyrazine-2-carboxamide derivatives as HTT (huntingtin) modulators for Huntington's disease treatment. The application names CHDI Foundation, Inc. as applicant and lists 13 inventors including Liu, Dominguez, Plotnikov, Haughan, Stott, Cosgrove, Clissold, Vater, Spencer, Esmieu, Malagu, and Chambers. The IPC classifications span C07D chemical compound classes (403/14, 413/14, 405/14, 471/10, 471/04), A61K pharmaceutical compositions (31/497), and A61P therapeutic activity (25/14 for CNS disorders).
Pharmaceutical companies and biotech firms engaged in Huntington's disease drug development should review this filing for freedom-to-operate considerations. The patent's broad claim scope covering HTT modulators with specific structural features may affect competitive positioning in the neurodegeneration therapeutic space. Research institutions and investors in Huntington's disease programs should monitor CHDI Foundation's IP portfolio for exclusivity implications.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
Publication EP4433471A1 Kind: A1 Apr 15, 2026
Applicants
CHDI Foundation, Inc.
Inventors
LIU, Longbin, DOMINGUEZ, Celia, PLOTNIKOV, Nikolay V., HAUGHAN, Alan, STOTT, Andrew, COSGROVE, Brett, CLISSOLD, Cole, VATER, Huw, SPENCER, Jonathan, ESMIEU, William, MALAGU, Karine, CHAMBERS, Mark
IPC Classifications
C07D 403/14 20060101AFI20230526BHEP C07D 413/14 20060101ALI20230526BHEP C07D 405/14 20060101ALI20230526BHEP C07D 471/10 20060101ALI20230526BHEP C07D 471/04 20060101ALI20230526BHEP A61K 31/497 20060101ALI20230526BHEP A61P 25/14 20060101ALI20230526BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.